Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2,3 USD | -5,74% | -3,36% | +18,56% |
Vakgebied
Aantal werknemers: 224
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
T-Cell Therapies
100,0
%
| 85 | 100,0 % | 0 | 100,0 % | -99,85% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 85 | 100,0 % | 0 | 100,0 % | -99,85% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 01-05-21 |
Charles Newton
DFI | Director of Finance/CFO | 53 | 01-02-21 |
Stephen Hill
COO | Chief Operating Officer | 53 | 01-06-19 |
Gary Lee
CTO | Chief Tech/Sci/R&D Officer | 47 | 31-01-22 |
Richard D. Goold
CTO | Chief Tech/Sci/R&D Officer | 64 | 01-04-19 |
Ellen Rose
IRC | Investor Relations Contact | - | 01-04-21 |
Matthew Lang
LAW | General Counsel | 48 | 05-07-23 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 01-05-21 |
Robert Nelsen
BRD | Director/Board Member | 60 | 01-09-18 |
Otis Brawley
BRD | Director/Board Member | 64 | 01-04-21 |
William Rieflin
BRD | Director/Board Member | 64 | 01-05-20 |
Richard Klausner
CEO | Chief Executive Officer | 72 | 01-06-18 |
Director/Board Member | 63 | 01-08-18 | |
Hans Bishop
BRD | Director/Board Member | 59 | 01-08-18 |
Elizabeth Nabel
BRD | Director/Board Member | 72 | 01-04-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 254 096 311 | 206 158 820 ( 81,13 %) | 0 | 81,13 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
CERo Therapeutics Holdings, Inc.
3.35% | 499 999 | 3.35% | 1 534 997 $ |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,56% | 586 mln. | |
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,86% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-8,49% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |
- Beurs
- Aandelen
- Koers LYEL
- Onderneming Lyell Immunopharma, Inc.